2015
DOI: 10.1016/j.metabol.2015.07.011
|View full text |Cite
|
Sign up to set email alerts
|

Novel therapies for osteoporosis

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

0
43
0
1

Year Published

2016
2016
2023
2023

Publication Types

Select...
9

Relationship

0
9

Authors

Journals

citations
Cited by 66 publications
(44 citation statements)
references
References 128 publications
(142 reference statements)
0
43
0
1
Order By: Relevance
“…The identification and validation of novel biomarkers for osteoporosis is a high priority not only for identifying patients at high risk for fracture and monitoring the efficacy of anti-resorptive therapies, but also for defining novel therapeutic strategies (Makras et al, 2015). Despite great advances in the understanding of mechanisms in bone metabolism over the past few years, major limitations still exist in managing osteoporosis.…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…The identification and validation of novel biomarkers for osteoporosis is a high priority not only for identifying patients at high risk for fracture and monitoring the efficacy of anti-resorptive therapies, but also for defining novel therapeutic strategies (Makras et al, 2015). Despite great advances in the understanding of mechanisms in bone metabolism over the past few years, major limitations still exist in managing osteoporosis.…”
Section: Discussionmentioning
confidence: 99%
“…In osteoporosis, the balance between osteoclast and osteoblast activities is disrupted. The dysregulation of bone resorbing osteoclasts significantly contributes to aging and drug-induced osteoporosis (Makras et al, 2015). MicroRNAs (miRNAs) are a class of endogenous, non-coding, singlestranded RNAs 19-24 nucleotides in length, which block translation or initiate transcript degradation via binding to the 3'-untranslated region (3'-UTR) of target mRNAs (Zamore and Haley, 2005).…”
Section: Introductionmentioning
confidence: 99%
“…A single dose administered to ovariectomized rats led to a maximum increase of 14% in vertebral BMD compared to a temporary 5% increase with daily PTH administration [53]. Various drugs have also been chemically modified or conjugated with the phosphate-carbon-phosphate (P-C-P) moiety that characterizes bisphosphonates to increase affinity for the bone surface.…”
Section: Osteoporosis Treatmentsmentioning
confidence: 99%
“…Odanacatib, an inhibitor of cathepsin K, exhibits similar bone protection effects, and approval can be expected soon. Other agents, such as a PTH-related peptide (PTHrp) analog and a Src tyrosine kinase inhibitor, are at the stage of clinical or preclinical evaluations (Makras et al, 2015;Suresh and Abrahamsen, 2015).…”
Section: Op (Osteoporosis)mentioning
confidence: 99%